Terns Pharmaceuticals/$TERN
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Terns Pharmaceuticals
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
Ticker
$TERN
Sector
Primary listing
Employees
59
Headquarters
Website
TERN Metrics
BasicAdvanced
$4B
-
-$1.03
-0.03
-
Price and volume
Market cap
$4B
Beta
-0.03
52-week high
$48.26
52-week low
$1.87
Average daily volume
5.6M
Financial strength
Current ratio
19.516
Quick ratio
19.213
Long term debt to equity
0.201
Total debt to equity
0.362
Profitability
EBITDA (TTM)
-108.331
Effective tax rate (TTM)
-0.25%
Management effectiveness
Return on assets (TTM)
-19.94%
Return on equity (TTM)
-29.12%
Valuation
Price to book
13.73
Price to tangible book (TTM)
13.73
Price to free cash flow (TTM)
-52.56
Free cash flow yield (TTM)
-1.90%
Free cash flow per share (TTM)
-0.849
Growth
Earnings per share change (TTM)
-12.41%
3-year earnings per share growth (CAGR)
-20.49%
What the Analysts think about TERN
Analyst ratings (Buy, Hold, Sell) for Terns Pharmaceuticals stock.
TERN Financial Performance
Revenues and expenses
TERN Earnings Performance
Company profitability
TERN News
AllArticlesVideos
Terns Pharmaceuticals' Leukemia Drug Seen As Potential Disruptor In CML Treatment Landscape, Analyst Upgrades
Benzinga·1 month ago
Why Is Terns Pharmaceuticals Stock Trading Lower After Obesity Trial Data?
Benzinga·2 months ago
Terns Pharma ends obesity drug program after mid-stage trial data
Reuters·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Terns Pharmaceuticals stock?
Terns Pharmaceuticals (TERN) has a market cap of $4B as of December 11, 2025.
What is the P/E ratio for Terns Pharmaceuticals stock?
The price to earnings (P/E) ratio for Terns Pharmaceuticals (TERN) stock is 0 as of December 11, 2025.
Does Terns Pharmaceuticals stock pay dividends?
No, Terns Pharmaceuticals (TERN) stock does not pay dividends to its shareholders as of December 11, 2025.
When is the next Terns Pharmaceuticals dividend payment date?
Terns Pharmaceuticals (TERN) stock does not pay dividends to its shareholders.
What is the beta indicator for Terns Pharmaceuticals?
Terns Pharmaceuticals (TERN) has a beta rating of -0.03. This means that it has an inverse relation to market volatility.